HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 622-631

  Dent, Susan ^a   Oyan, Basak ^b   Honig, Arnd ^c   Mano, Max ^d   Howell, Sacha ^e  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b YEDITEPE UNIVERSITY   (Turkey)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

HER2; Lapatinib; Neoadjuvant breast cancer; Novel agents; Pathological complete response; Pertuzumab; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NERATINIB; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEART DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2;

EID: 84878926256     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.01.002     Document Type: Review

References (88)

1. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:188-194.
2. van der Hage J.H., van de Velde C.J., Mieog J.S. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007, 2. CD005002. 10.1002/1465185.
3. Chevallier B., Roche H., Olivier J.P., et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993, 16:223-228.
4. Sinn H.P., Schmid H., Junkermann H., et al. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 1994, 54:552-558.
5. Sataloff D.M., Mason B.A., Prestipino A.J., et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995, 180:297-306.
6. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
7. Symmans W.F., Peintinger F., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 2007, 25:4414-4422.
8. Penault-Llorca F., Abrial C., Raoelfils I., et al. Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol 2008, 39:1221-1228.
9. Mukai H., Watanabe T., Ando M., et al. Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed. Breast Cancer Res Treat 2009, 113:123-128.
10. Ross J.S., Slodkowska E.A., Symmans W.F., et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
11. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med 2001, 15:783-792.
12. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
13. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
14. Loibl S., von Minckwitz G., Blohmer J.U., et al. pCR as a surrogate in HER2-positive patients treated with trastuzumab. Cancer Res 2011, 71(S24):64s. Abstract S5-4.
15. Burstein H.J., Harris L.N., Gelman R., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003, 21:46-53.
16. Jinno H., Sato T., Takahashi M., et al. A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer. J Clin Oncol 2011, 29(S15). Abstract e11070.
17. Coudert B.P., Arnould L., Moreau L., et al. Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 2006, 17:409-414.
18. Paepke S., Kiechle M., Paepke D., et al. Interim analysis of the multicenter phase II HEDON trial evaluating pathological response to pre-operative docetaxel and docetaxel+trastuzumab (T) in locally advanced breast cancer (BR) stratified by HER2-status. J Clin Oncol 2009, 27(S15). Abstract e11512.
19. Sawaki M., Iwata H., Sato Y., et al. Phase II study of preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER-2-overexpressing breast cancer. Breast 2005, 19:370-376.
20. Bines J., Murad A., Lago S., et al. Weekly docetaxel (Taxotere®) and trastuzumab (Herceptin®) as primary therapy in stage III, HER-2 overexpressing breast cancer: A Brazilian multicenter Study. Breast Cancer Res Treat 2003, 82(S1):S56. Abstract 243.
21. Masuda N., Ando M., Aogi K., et al. Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2. J Clin Oncol 2009, 27(15S):S22. Abstract 565.
22. Chollet P.J., Dubray P., Durando X., et al. Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT). J Clin Oncol 2009, 27(S15). Abstract e11560.
23. Saeki T., Aogi K., Nakamura S., et al. Multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer. J Clin Oncol 2010, 28(S15):S112. Abstract 681.
24. Untch M., Fasching P.A., Konecny G.E., et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011, 29:3351-3357.
25. Blakely L., Somer B., Keaton M., et al. Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer. J Clin Oncol 2009, 27(S29). Abstract 595.
26. Robidoux A., Buzdar A.U., Quinaux E., et al. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010, 10:81-86.
27. Hyams D., Leichman G., Klein P., et al. Phase II trial of neoadjuvant pegylated liposomal doxorubicin with paclitaxel and trastuzumab in patients with operable Her2-positive breast cancer. Cancer Res 2009, 69(S3):24. Abstract 1098.
28. Antón A., Ruiz A., Plazaola A., et al. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 2011, 22:74-79.
29. Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031.
30. Chia S., Bryce C., Pansegrau G., et al. Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): A multi-centre study from British Columbia. Breast 2009, 18(S1):S6. Abstract 0170.
31. Al-Tweigeri T.A., Ajarim D.S., Alsayed A.A., et al. Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol 2010, 27:571-577.
32. Sánchez-Muñoz A., Dueñas-García R., Jaén-Morago A., et al. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine±trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 2010, 33:432-437.
33. Hurley J., Doliny P., Reis I., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006, 24:1831-1838.
34. Coudert B.P., Largillier R., Arnould L., et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007, 25:2678-2684.
35. Dirix L.Y., Prove A., Sweldens C., et al. Phase II study of docetaxel, carboplatin and trastuzumab (THC) in patients with locally advanced breast cancer. J Clin Oncol 2007, 25(S15):S18. Abstract 1062.
36. Bayraktar S., Bayraktar U.D., Reis I.M., et al. Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer. J Clin Oncol 2009, 27(S). Abstract e11557.
37. Zeynalova K.R., Vishnevskaya Y.V., Ganshina I.P. High pathological complete response rate of neo-adjuvant combination of docetaxel, carboplatin and trastuzumab in patients with HER2-overexpressing breast cancer: preliminary results. Eur J Cancer 2008, 8(S):93-94.
38. Sikov W.M., Dizon D.S., Strenger R., et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol 2009, 27:4693-4700.
39. Chen X., Chen C., Wu J., et al. Weekly paclitaxel plus carboplatin +/- trastuzumab in preoperative therapy of Her2-neu over-expressing breast cancer: a pilot phase II study. Breast 2009, 18(S1):63-64. Abstract 0180.
40. Tripathy D., Moisa C., Gluck S. An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2-) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC. Eur J Cancer 2007, 5(S):223. Abstract 2129.
41. Perez Manga G., Khosravi-Shahi P., Izarzugaza Peron Y., et al. Phase II study of neoadjuvant treatment with docetaxel, capecitabine, and trastuzumab in HER-2-positive locally advanced or inflammatory breast cancer: TXH trial. J Clin Oncol 2009, 27(S15). Abstract e11581.
42. Wildiers H., Neven P., Christiaens M.R., et al. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 2011, 22:588-594.
43. Limentani S.A., Brufsky A.M., Erban J.K., et al. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007, 25:1232-1238.
44. Im S.A., Lee K.S., Ro J., et al. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01. Breast Cancer Res Treat 2012, 132:589-600.
45. Harris L.N., Eklund A.C., Carter S., et al. HER2 tumors are heterogeneous, clinically, molecularly, and in response to preoperative trastuzumab: pathway analysis of gene expression profiles from three breast cancer datasets. Breast Cancer Res Treat 2007, 106(S1):S87. Abstract 2009.
46. Torrisi R., Magni E., Dellapasqua S., et al. Trastuzumab and oral vinorelbine (+/- endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer. Breast Cancer Res Treat 2006, 100(S1):148. Abstract 3071.
47. Torrisi R., Cardillo A., Cancello G., et al. Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin Breast Cancer 2010, 10:483-488.
48. Zubkus J.D., Daniel D.B., Eakle J.F., et al. Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial. J Clin Oncol 2011, 29(S15 Pt 1):S75. Abstract 621.
49. Smith J.W., Buyse M., Rastogi P., et al. Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): a phase II trial of the NSABP Foundation Research Group. J Clin Oncol 2009, 27(S15 Pt 1):S26. Abstract 580.
50. Viens P., Pierga J., Petit T., et al. Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEVERLY2 study. J Clin Oncol 2011, 29(S15 Pt 1):S52. Abstract 531.
51. Yardley D.A., Raefsky E., Castillo R., et al. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer 2011, 11:297-305.
52. Chang J.C.N., Mayer I.A., Forero-Torres A., et al. TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J Clin Oncol 2011, 9(S15 Pt 1):S46. Abstract 505.
53. Callahan R.D., Patel R., Chan D., et al. Phase II trial of presurgical treatment with trastuzumab (H) or lapatinib (Ty) or the combination of trastuzumab and lapatinib (H+Ty), followed by six cycles of docetaxel (T) and carboplatin (C) with trastuzumab (TCH) or lapatinib (TCTy) or the combination of trastuzumab and lapatinib (TCHTy) in patients with HER2+ breast cancer. Cancer Res 2010, 71(S):169S. Abstract P1-11-12.
54. Kaklamani V.G., Siziopikou K., Scholtens D., et al. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat 2012, 132:833-842.
55. Boussen H., Cristofanilli M., Zaks T., et al. Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. J Clin Oncol 2010, 28(20):3248-3255.
56. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
57. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
58. Pierga J.Y., Delaloge S., Espié M., et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010, 122:429-437.
59. Steger G., Greil R., Jakesz R., et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC plus trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Res 2009, 69(S24):S64s. Abstract 1081.
60. Baselga J., Bradbury I., Eidtmann H., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012, 379:633-640.
61. Untch M., Loibl S., Bischoff J., et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012, 13:135-144.
62. Holmes F.A., Nagarwala Y.M., Espina V.A., et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol 2011, 29(S15):46s. Abstract 506.
63. Guarneri V., Frassoldati A., Bottini A., et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012, 30:1989-1995.
64. Gianni L., Pienkowski T., Im Y.H., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
65. Dawood S., Gonzalez-Angulo A.M., Peintinger F., et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer 2007, 110:1195-1200.
66. Bayraktar S., Gonzalez-Angulo A.M., Lei X., et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer 2012, 118:2385-2393.
67. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Breast cancer screening and diagnosis, v.1.2010. ; 2012 [01.05.12].
68. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
69. Aebi S., Davidson T., Gruber G., et al. ESMO guidelines working group. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(S6):vi12-vi24.
70. Robidoux A., Tang G., Rastogi P., et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. J Clin Oncol 2012, 30(Suppl.). Abstract LBA506.
71. de Azambuja E., Bedard P.L., Suter T., et al. Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?. Target Oncol 2009, 4:77-88.
72. Moy B., Goss P. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007, 12:756-765.
73. Schneeweiss A., Chia S., Hickish T., et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res 2011, 7(S):112s. Abstract S5-S6.
74. Bozovic-Spasojevic I., Azim H.T., Paesmans M., et al. Neoajduvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?. Lancet Oncol 2011, 12(3):209-211.
75. Baselga J., Cortés J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
76. Bedard P.L., de Azambuja E., Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets 2009, 9:148-162.
77. Burstein H.J., Sun Y., Dirix L.Y., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28:1301-1307.
78. Lewis Phillips G.D., Li G., Dugger D.L., et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008, 68:9280-9290.
79. Vogel C.L., Burris H.A., Limentani S., et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): final results. J Clin Oncol 2009, 27(S15):S44. Abstract 1017.
80. Herceptin. EMA/CHMP/897580/2011, European Medicines Agency, 2011.
81. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
82. Pivot X., Romieu G., Bonnefoi H., et al. PHARE Trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Ann Oncol 2012, 23(Suppl. 9):ixe2. Abstract LBA5.
83. Witzel I., Loibl S., von Minckwitz G., et al. Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab - a translational project in the neoadjuvant GeparQuinto trial. Br J Cancer 2012, 107:956-960.
84. Riethdorf S., Müller V., Zhang L., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010, 16:2634-2645.
85. Azim H.A., Rothe F., Aura C.M., et al. Correlation between circulating tumor cells (CTCs), PET/CT response and pathological complete response (pCR) in primary Her2-positive breast cancer patients: a sub-study from the NeoALTTO trial. Ann Oncol 2012, 23(Suppl. 9):ix98. Abstract 255PD.
86. Shah C., Miller T.W., Wyatt S.K., et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 2009, 15:4712-4721.
87. Mittendorf E.A., Wu Y., Scaltriti M., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009, 15:7381-7388.
88. von Minckwitz G., Eidtmann H., Loibl S., et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011, 22:301-306.